27Common Terminology Criteria for Adverse Events Version 4.03, National Institute of Health, National Cancer Institute; 2010. 28Guidance for Industry S9: Nonclinical evalu ation for anticancer pharmaceuticals. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2010. 29Characterization of the Antitumor Effects of An ti-ICOS Antibody Isotypes Alone or Combined with Anti-PD-1 in a CT26 Tumor Model (Experiment No. 1804-010 and BDX1804-102).